Joel C. Sunshine
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joel C. Sunshine has a total of 379 co-authors. Here are the top co-authors by number of shared publications:
- Jordan J. Green
Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, USA
26 shared publications - Janis Taube
Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Kimmel Cancer Center, Baltimore, MD
8 shared publications - Stephany Y. Tzeng
Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
8 shared publications Aleksandra Ogurtsova
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland
6 shared publicationsHaiying Xu
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; The Mark Foundation Center for Advanced Genomics and Imaging, Johns Hopkins University, Baltimore, Maryland; Bloomberg∼Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
5 shared publications- Evan J. Lipson
Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
4 shared publications
Latest Publications
- 10 September 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 408
Area deprivation and melanoma-specific mortality in a high-risk referral cohort of patients with thin melanoma: a retrospective cohort study
- 10 September 2026
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 318 (1) , 408
Area deprivation and melanoma-specific mortality in a high-risk referral cohort of patients with thin melanoma: a retrospective cohort study
- Open Access
- 24 August 2026
- Published by Wiley in Advanced Science
Single‐Dose TACE‐Like Injection of Sustained‐Release Panobinostat/IL‐12 Polymeric Microparticles is Effective in Preclinical Liver Cancer Models
Background & Aims : Primary liver cancer is the third leading cause of cancer death worldwide, and about 70% of hepatocellular carcinomas (HCCs) do not respond to systemic immunotherapies. Transarterial chemoembolization (TACE) remains standard treatment for intermediate‐stage HCC, but long‐term survival is poor. We aimed to develop a polymeric TACE‐like platform to sensitize liver cancer to checkpoint inhibitors by enabling sustained co‐delivery of panobinostat and IL‐12. Methods : Patient‐derived liver cancer organoids were used to screen drugs and identify panobinostat as a cytotoxic agent. We then formulated sustained‐release microparticles from anionic poly(lactic‐co‐glycolic acid) (PLGA) and cationic poly(beta‐amino ester) (PBAE) for combined delivery of panobinostat and IL‐12, and tested the system in three liver cancer models. Results : The microparticles achieved tumor‐specific retention and sustained release for two weeks following a single intratumoral or intrahepatic arterial injection. This led to tumor inhibition and prolonged survival in orthotopic liver cancer models. Mechanistically, treatment promoted tertiary lymphoid structure formation, increased infiltration of immune cells, and elevated pro‐inflammatory cytokines, triggering innate and adaptive antitumor immune responses. Conclusions : A PLGA/PBAE sustained‐release microparticle platform was successfully developed for TACE‐like co‐delivery of panobinostat and IL‐12. This combined chemoimmunotherapy strategy shows promise for overcoming immune suppression and improving liver cancer treatment.
- 24 August 2026
- Published by Wiley in Advanced Science
Open AccessSingle‐Dose TACE‐Like Injection of Sustained‐Release Panobinostat/IL‐12 Polymeric Microparticles is Effective in Preclinical Liver Cancer Models
Background & Aims : Primary liver cancer is the third leading cause of cancer death worldwide, and about 70% of hepatocellular carcinomas (HCCs) do not respond to systemic immunotherapies. Transarterial chemoembolization (TACE) remains standard treatment for intermediate‐stage HCC, but long‐term survival is poor. We aimed to develop a polymeric TACE‐like platform to sensitize liver cancer to checkpoint inhibitors by enabling sustained co‐delivery of panobinostat and IL‐12. Methods : Patient‐derived liver cancer organoids were used to screen drugs and identify panobinostat as a cytotoxic agent. We then formulated sustained‐release microparticles from anionic poly(lactic‐co‐glycolic acid) (PLGA) and cationic poly(beta‐amino ester) (PBAE) for combined delivery of panobinostat and IL‐12, and tested the system in three liver cancer models. Results : The microparticles achieved tumor‐specific retention and sustained release for two weeks following a single intratumoral or intrahepatic arterial injection. This led to tumor inhibition and prolonged survival in orthotopic liver cancer models. Mechanistically, treatment promoted tertiary lymphoid structure formation, increased infiltration of immune cells, and elevated pro‐inflammatory cytokines, triggering innate and adaptive antitumor immune responses. Conclusions : A PLGA/PBAE sustained‐release microparticle platform was successfully developed for TACE‐like co‐delivery of panobinostat and IL‐12. This combined chemoimmunotherapy strategy shows promise for overcoming immune suppression and improving liver cancer treatment.
- 6 March 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (1) , 229-231
Pain and scrotal involvement are associated with misdiagnosis in extramammary Paget disease: A retrospective cohort study
- 6 March 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (1) , 229-231
Pain and scrotal involvement are associated with misdiagnosis in extramammary Paget disease: A retrospective cohort study
- Open Access
Acellular Adipose Tissue promotes anti-fibrotic remodeling in Phase II Study
Summary: Acellular Adipose Tissue (AAT) is an off-the-shelf, cadaveric adipose-derived ECM-based biomaterial for soft tissue reconstruction. AAT has been validated preclinically to promote angiogenesis and adipogenesis and demonstrated safety, biocompatibility, and tolerability in a Phase I study. In this study we report the findings for the first ten patients in the Phase II study for permanent reconstruction of modest soft tissue defects. AAT promoted macrophages, CD3 + T cells, and CD34 + progenitor activity. Multiplex immunofluorescence staining using the PhenoCycler (formerly CODEX) imaging platform found that AAT can induce tertiary lymphoid structures (TLS). Nanostring GEOMx spatial transcriptional data analysis found significant differential gene expression between neighboring tissues with EGR1 , MCL1 , and NR4A1 upregulated in AAT. These genes have roles in angiogenesis, anti-apoptotic processes, and promotion of anti-inflammatory genes, respectively. AAT promoted anti-fibrotic CD74 + adipose-derived stromal cells, confirmed by immunofluorescence staining. Our findings demonstrate that AAT promotes angiogenesis, adipogenesis, and anti-fibrotic remodeling.
Open AccessAcellular Adipose Tissue promotes anti-fibrotic remodeling in Phase II Study
Summary: Acellular Adipose Tissue (AAT) is an off-the-shelf, cadaveric adipose-derived ECM-based biomaterial for soft tissue reconstruction. AAT has been validated preclinically to promote angiogenesis and adipogenesis and demonstrated safety, biocompatibility, and tolerability in a Phase I study. In this study we report the findings for the first ten patients in the Phase II study for permanent reconstruction of modest soft tissue defects. AAT promoted macrophages, CD3 + T cells, and CD34 + progenitor activity. Multiplex immunofluorescence staining using the PhenoCycler (formerly CODEX) imaging platform found that AAT can induce tertiary lymphoid structures (TLS). Nanostring GEOMx spatial transcriptional data analysis found significant differential gene expression between neighboring tissues with EGR1 , MCL1 , and NR4A1 upregulated in AAT. These genes have roles in angiogenesis, anti-apoptotic processes, and promotion of anti-inflammatory genes, respectively. AAT promoted anti-fibrotic CD74 + adipose-derived stromal cells, confirmed by immunofluorescence staining. Our findings demonstrate that AAT promotes angiogenesis, adipogenesis, and anti-fibrotic remodeling.
- Open Access
- 27 January 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (1) , e012856
Reprogramming the melanoma tumor immune microenvironment via combinatorial signal 2/3 gene delivery
Introduction: An adaptive immune response to cancer requires three main signals: antigen presentation and recognition (“signal 1”), costimulation (“signal 2”), and secreted immunostimulatory cytokines (“signal 3”). Expression of these signals in tumors via non-viral gene delivery represents a promising strategy to reprogram the tumor microenvironment (TME) and prime antitumor immunity. Methods: We used modular polymeric poly(beta-amino ester)-based nanoparticles (NPs) to investigate codelivery of plasmids encoding signal 3s (interleukin (IL)-2, IL-12, IL-15, IL-23, IL-35, or granulocyte-macrophage colony-stimulating factor) and signal 2s (4-1BBL, CD80, CD86, or OX40L) to B16F10 melanoma tumors in vivo. Downstream immune responses and impact on the TME were assessed via flow cytometry and spatial proteomics using a 27-marker PhenoCycler panel. Results: Ex vivo flow cytometry and PhenoCycler tissue analysis revealed that multiple signal 2/3 NP combinations led to decreased tumor growth, increased immune-cell infiltration, and skewing of adaptive and innate populations towards immunostimulatory phenotypes with increased CD8 + T-cell and M1 macrophage infiltration. Signal 2/3 NPs also drove antigen presentation on tumor and antigen-presenting cells (APCs) (macrophages, dendritic cells), and led to induction of major histocompatibility complex class I and class II on melanoma cells. Evaluation of putative biomarkers of treatment response to signal 2/3 NP delivery demonstrated that multiple markers of an inflamed TME correlated negatively with tumor growth, with antigen presentation induction highly correlated with tumor size reduction. Spatial analysis on top-performing NP formulations demonstrated that immune cell populations entered the TME via both the tumor–stroma interface and intratumoral vessels; CD8 + T cells and proinflammatory M1 macrophages were brought into proximity. Furthermore, top NP formulations increased the density of intratumoral CD8 + -CD4 + -proinflammatory APC triads, which have been identified as key structures for immunotherapy-mediated clearance of solid tumors. Conclusions: These results demonstrate the utility of a modular NP design for systematic screening of signal 2/3 delivery to melanoma in vivo and highlight the benefit of in-depth profiling via spatial proteomics to evaluate local antitumor immune responses. The results provide insight into the mechanisms underpinning this therapeutic reprogramming strategy, emphasizing the relationship between signal 2/3 NPs and their ability to drive signal 1 for productive antitumor responses in vivo.
- 27 January 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (1) , e012856
Open AccessReprogramming the melanoma tumor immune microenvironment via combinatorial signal 2/3 gene delivery
Introduction: An adaptive immune response to cancer requires three main signals: antigen presentation and recognition (“signal 1”), costimulation (“signal 2”), and secreted immunostimulatory cytokines (“signal 3”). Expression of these signals in tumors via non-viral gene delivery represents a promising strategy to reprogram the tumor microenvironment (TME) and prime antitumor immunity. Methods: We used modular polymeric poly(beta-amino ester)-based nanoparticles (NPs) to investigate codelivery of plasmids encoding signal 3s (interleukin (IL)-2, IL-12, IL-15, IL-23, IL-35, or granulocyte-macrophage colony-stimulating factor) and signal 2s (4-1BBL, CD80, CD86, or OX40L) to B16F10 melanoma tumors in vivo. Downstream immune responses and impact on the TME were assessed via flow cytometry and spatial proteomics using a 27-marker PhenoCycler panel. Results: Ex vivo flow cytometry and PhenoCycler tissue analysis revealed that multiple signal 2/3 NP combinations led to decreased tumor growth, increased immune-cell infiltration, and skewing of adaptive and innate populations towards immunostimulatory phenotypes with increased CD8 + T-cell and M1 macrophage infiltration. Signal 2/3 NPs also drove antigen presentation on tumor and antigen-presenting cells (APCs) (macrophages, dendritic cells), and led to induction of major histocompatibility complex class I and class II on melanoma cells. Evaluation of putative biomarkers of treatment response to signal 2/3 NP delivery demonstrated that multiple markers of an inflamed TME correlated negatively with tumor growth, with antigen presentation induction highly correlated with tumor size reduction. Spatial analysis on top-performing NP formulations demonstrated that immune cell populations entered the TME via both the tumor–stroma interface and intratumoral vessels; CD8 + T cells and proinflammatory M1 macrophages were brought into proximity. Furthermore, top NP formulations increased the density of intratumoral CD8 + -CD4 + -proinflammatory APC triads, which have been identified as key structures for immunotherapy-mediated clearance of solid tumors. Conclusions: These results demonstrate the utility of a modular NP design for systematic screening of signal 2/3 delivery to melanoma in vivo and highlight the benefit of in-depth profiling via spatial proteomics to evaluate local antitumor immune responses. The results provide insight into the mechanisms underpinning this therapeutic reprogramming strategy, emphasizing the relationship between signal 2/3 NPs and their ability to drive signal 1 for productive antitumor responses in vivo.
- Open Access
- 25 December 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (12) , e012235
AstroID resource: a scalable, relational database structure for longitudinal biomarker discovery
Background: The biological sciences are producing increasingly larger datasets for biomarker discovery. While common data models have been developed for medical terms as they relate to patient health outcomes, a data model that supports longitudinal tracking of biospecimens and relating them against an individual patient experience is a large, unmet need. Method: A structure and associated taxonomy were achieved through a six-tier build in Research Electronic Data CAPture (REDCap), which organizes the complexity of the therapeutic decisions, biospecimens, and outcomes that characterize a longitudinal patient experience. Modules were developed to support export of REDCap data into a Structured Query Language (SQL) format for merging with extended biomarker data, also housed in SQL. Results: The resultant AstroID resource is a relational structure for clinical and biospecimen data that meets several desired goals: searchable, flexible, generic, Health Insurance Portability and Accountability Act-compliant, auditable, and easy-to-use. The essential elements forming the core of the six-tiered build are provided, so others can readily adopt this schema, as well as an example of an extended, customized build to support biomarker discovery for patients with melanoma. Two examples where this data structure was used to support biomarker discovery and development are described, and example queries of the database are also presented. To the extent possible, the data dictionary was aligned with large data models, such as those for the National Institutes of Health’s Human Tumor Atlas Network. The structure can readily scale to accommodate thousands of patients, multimodality data, and spatial characterization of billions of cells. Radiologic imagery can also be included along with pathology imagery to support spatial studies, including artificial intelligence-driven analyses. Conclusions: This effort provides a database model for investigators conducting research on large volumes of biospecimens with clinical annotation. We have now deployed this structure in our laboratories and have over 1B cells spatially mapped, each effectively tagged with the clinical information from longitudinal patient experiences. While the description uses the example of cancer biomarkers, this data structure could be used to characterize longitudinal biospecimens from any disease process. In the near future, automatic synchronization between the electronic medical record and one or more AstroID databases is anticipated.
- 25 December 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (12) , e012235
Open AccessAstroID resource: a scalable, relational database structure for longitudinal biomarker discovery
Background: The biological sciences are producing increasingly larger datasets for biomarker discovery. While common data models have been developed for medical terms as they relate to patient health outcomes, a data model that supports longitudinal tracking of biospecimens and relating them against an individual patient experience is a large, unmet need. Method: A structure and associated taxonomy were achieved through a six-tier build in Research Electronic Data CAPture (REDCap), which organizes the complexity of the therapeutic decisions, biospecimens, and outcomes that characterize a longitudinal patient experience. Modules were developed to support export of REDCap data into a Structured Query Language (SQL) format for merging with extended biomarker data, also housed in SQL. Results: The resultant AstroID resource is a relational structure for clinical and biospecimen data that meets several desired goals: searchable, flexible, generic, Health Insurance Portability and Accountability Act-compliant, auditable, and easy-to-use. The essential elements forming the core of the six-tiered build are provided, so others can readily adopt this schema, as well as an example of an extended, customized build to support biomarker discovery for patients with melanoma. Two examples where this data structure was used to support biomarker discovery and development are described, and example queries of the database are also presented. To the extent possible, the data dictionary was aligned with large data models, such as those for the National Institutes of Health’s Human Tumor Atlas Network. The structure can readily scale to accommodate thousands of patients, multimodality data, and spatial characterization of billions of cells. Radiologic imagery can also be included along with pathology imagery to support spatial studies, including artificial intelligence-driven analyses. Conclusions: This effort provides a database model for investigators conducting research on large volumes of biospecimens with clinical annotation. We have now deployed this structure in our laboratories and have over 1B cells spatially mapped, each effectively tagged with the clinical information from longitudinal patient experiences. While the description uses the example of cancer biomarkers, this data structure could be used to characterize longitudinal biospecimens from any disease process. In the near future, automatic synchronization between the electronic medical record and one or more AstroID databases is anticipated.
- Open Access
- 21 December 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (12) , e012280
Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI)
Multiplex immunofluorescence and immunohistochemistry (mIF/IHC) are increasingly employed antibody-based technologies that use tissue sparingly and facilitate the detection of co-localized or neighboring biomarkers. Specifically, these platforms enable spatial analyses of the tumor microenvironment as well as extended applications, for example, describing normal tissue anatomy, autoimmunity, infectious diseases, etc. mIF/IHC has greatly enhanced biomarker discovery efforts, and a growing number of studies suggest superiority to traditional IHC. Standardization of staining approaches, reporting of image analysis strategies and resultant data is critical for facilitating cross-study comparisons, validation, deployment, and generalization of findings. To address this challenge, The Society for Immunotherapy of Cancer (SITC) previously published two articles providing best practice guidelines for mIF/IHC staining, image analysis, and data sharing. Here, SITC convened stakeholders to develop the third article in the series, a consensus checklist for scientific reporting of mIF/IHC data to support and complement the best practice guidelines. The checklist includes critical components of mIF/IHC applications to be defined within publications such as detailed descriptions of analytical validation; image acquisition, selection, and registration methods; and cell clustering and spatial analysis strategies, amongst others. Such information will help with data reproducibility and comparison across studies towards future drug and assay development.
- 21 December 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (12) , e012280
Open AccessSociety for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI)
Multiplex immunofluorescence and immunohistochemistry (mIF/IHC) are increasingly employed antibody-based technologies that use tissue sparingly and facilitate the detection of co-localized or neighboring biomarkers. Specifically, these platforms enable spatial analyses of the tumor microenvironment as well as extended applications, for example, describing normal tissue anatomy, autoimmunity, infectious diseases, etc. mIF/IHC has greatly enhanced biomarker discovery efforts, and a growing number of studies suggest superiority to traditional IHC. Standardization of staining approaches, reporting of image analysis strategies and resultant data is critical for facilitating cross-study comparisons, validation, deployment, and generalization of findings. To address this challenge, The Society for Immunotherapy of Cancer (SITC) previously published two articles providing best practice guidelines for mIF/IHC staining, image analysis, and data sharing. Here, SITC convened stakeholders to develop the third article in the series, a consensus checklist for scientific reporting of mIF/IHC data to support and complement the best practice guidelines. The checklist includes critical components of mIF/IHC applications to be defined within publications such as detailed descriptions of analytical validation; image acquisition, selection, and registration methods; and cell clustering and spatial analysis strategies, amongst others. Such information will help with data reproducibility and comparison across studies towards future drug and assay development.
- 16 October 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (4) , 1143-1146
PD-L1–Negative Macrophages Are Associated with Poor Outcomes and High-Grade Immune-Related Adverse Event Development in Patients with Melanoma Receiving Anti–PD-1 Immunotherapy
- 16 October 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (4) , 1143-1146
PD-L1–Negative Macrophages Are Associated with Poor Outcomes and High-Grade Immune-Related Adverse Event Development in Patients with Melanoma Receiving Anti–PD-1 Immunotherapy
- 8 October 2025
- Published by Springer Nature in Cancer and Metastasis Reviews
- Vol. 44 (4) , 1-20
Spatial proteomics for investigating solid tumor resistance mechanisms
Spatial proteomics technologies have been pivotal in profiling tumor immune microenvironments at single-cell resolution, advancing our understanding of cancer biology, identifying key cell populations in solid tumors, and predicting treatment responses. Although immune checkpoint and molecular inhibitors have revolutionized cancer care, resistance mechanisms remain a major therapeutic challenge that hinder productive responses in a notable fraction of cancer patients. In this review, we outline current spatial proteomics and computational analysis tools for studying the tumor immune microenvironment and discuss how spatial proteomics techniques have helped elucidate cancer resistance mechanisms across multiple tumor types. In this process, we highlight the importance of investigating immunosuppressive cell populations that can mediate cancer resistance, specifically with regard to their localization, protein signatures, and surrounding interactions. Finally, we provide a look ahead at future applications of artificial intelligence/machine learning and multi-omics approaches that will help further propel our understanding of cancer resistance mechanisms through spatial biology research.
- 8 October 2025
- Published by Springer Nature in Cancer and Metastasis Reviews
- Vol. 44 (4) , 1-20
Spatial proteomics for investigating solid tumor resistance mechanisms
Spatial proteomics technologies have been pivotal in profiling tumor immune microenvironments at single-cell resolution, advancing our understanding of cancer biology, identifying key cell populations in solid tumors, and predicting treatment responses. Although immune checkpoint and molecular inhibitors have revolutionized cancer care, resistance mechanisms remain a major therapeutic challenge that hinder productive responses in a notable fraction of cancer patients. In this review, we outline current spatial proteomics and computational analysis tools for studying the tumor immune microenvironment and discuss how spatial proteomics techniques have helped elucidate cancer resistance mechanisms across multiple tumor types. In this process, we highlight the importance of investigating immunosuppressive cell populations that can mediate cancer resistance, specifically with regard to their localization, protein signatures, and surrounding interactions. Finally, we provide a look ahead at future applications of artificial intelligence/machine learning and multi-omics approaches that will help further propel our understanding of cancer resistance mechanisms through spatial biology research.
- 9 June 2025
- Published by Elsevier in Laboratory Investigation
- Vol. 105 (10) , 104203
Siglec Ligand Immunohistochemistry Reveals Association With Immune Exclusion and Survival
- 9 June 2025
- Published by Elsevier in Laboratory Investigation
- Vol. 105 (10) , 104203
Siglec Ligand Immunohistochemistry Reveals Association With Immune Exclusion and Survival